Regen BioPharma Inc (RGBP)

[9754LB851]

The new data demonstrates enhanced ability to reduce cancer growth in an efficacious manner while appearing not to induce any form of toxicity.


NR2F6 using patent-pending compounds developed by the Company results in selective inhibition of new blood vessels under conditions associated with cancer and wet macular degeneration. The data, which was obtained using human umbilical vein endothelial cells (HUVEC)

https://www.otcmarkets.com/stock/RGBP/news/story?e&id=1467301

https://finance.yahoo.com/news/regen-biopharma-inc-files-immuno-123000937.html


If the market ever takes a liking to this stock... anyhow undervalued JMHO $RGBP





https://www.otcmarkets.com/stock/RGBP/security


https://www.regenbiopharmainc.com/products.html


Regen BioPharma Successfully Treats Rheumatoid Arthritis Using Cannabidiol (CBD) Based Immune Modulatory Treatments 10/03/2019


Regen BioPharma Discovers Potential New Way to Improve Outcomes from Cancer Surgery Using Combination of Cannabidiol and NR2F6 Inhibition 08/15/2019